Nevro

Nevro Corp. is a global medical device company headquartered in Redwood City, California. The company focuses on delivering comprehensive solutions for the treatment of chronic pain. Its primary offering is the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform that utilizes proprietary 10 kHz Therapy. This therapy enables patients to achieve sustained pain relief without paresthesia, the uncomfortable shocking or jolting sensations associated with traditional SCS systems.

In 2015, Nevro received FDA approval for the Senza SCS System to deliver all available SCS frequencies and waveform types. The company's Senza, Senza II, and Senza Omnia are the only SCS systems capable of delivering the proprietary 10 kHz Therapy. As of January 2022, Nevro's solutions have impacted the lives of over 80,000 patients globally.

Nevro's comprehensive HFX product platform includes the Senza SCS system and support services for treating chronic trunk, limb pain, and painful diabetic neuropathy. In July 2021, the company's landmark SENZA-PDN randomized controlled trial led to FDA approval of the HFX system with a specific indication for treating painful diabetic neuropathy, a first for any SCS system.

In October 2022, Nevro received FDA approval for its new manufacturing facility in Costa Rica's Coyol Free Trade Zone. This global operation aims to ensure greater controls, efficiency, and flexible capacity while maintaining the highest quality standards as the company scales production.